AIDD received innovation grant received from Swiss Commission for Technology and Innovation
Alpine Institute for Drug Discovery (AIDD) and University of Geneva have received a 238’000 CHF grant from the Swiss Commission for Technology and Innovation (CTI) to pursue early stage research on a novel undisclosed target addressing unmet needs in inflammation using a novel and unique multi-dimensional approach.
In the project AIDD will collaborate with the laboratory of Professor Leonardo Scapozza of the School of Pharmaceutical Sciences (EPGL) at the University of Geneva to perform assay development, screening, and hit validation.
AIDD’s novel approach
AIDD’s technology platform offers a new opportunity to tackle new classes of targets through a novel combination of three cutting edge technologies: identification of allosteric pockets with nanobodies, small molecule fragment screening by NMR, and the use of ultra-sensitive sensitive functional AURA assays. Synergistic use of these three technologies will help AIDD successfully identify and optimize small molecule therapeutics targeting new classes of targets where previous efforts have failed.
About AIDD
The Alpine Institute for Drug Discovery is an enterprise founded in 2013 and based at EPFL Innovation Park aiming at creating shared value for the community and serving academic researchers and technology transfer offices, especially in the Alpine region, by commercializing academic discoveries with therapeutic potential. Working in collaboration with academic partners, AIDD co-creates new intellectual property by discovering potential therapeutic drugs using its cutting-edge discovery platform.
AIDD will seek to drive selected immunotherapy discovery projects from assay design for primary screening through to the final stages of lead optimization, such that molecules achieve preclinical validation and demonstrate high-potential ADMET profiles. Individual projects are expected to take three to five years and cost CHF3-5 million per project, depending on the complexity. The intellectual property created in each project will be placed in an AIDD sponsored special purpose vehicle (SPV), the ownership of which will be shared between AIDD, academic partners and investors. Some SPVs will be the source of new startup companies while other SPVs will be sold to pharmaceutical companies who have the infrastructure and competencies to complete clinical development, regulatory submissions, manufacturing, sales & marketing.
0Comments
Please login or sign up to comment.
Commenting guidelines